Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_assertion type Assertion NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_head.
- NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_assertion description "[A clinical trial with the sPLA(2) inhibitor varespladib methyl was recently terminated, while clinical trials with the Lp-PLA(2) inhibitor darapladib are being conducted in coronary heart disease patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_provenance.
- NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_assertion evidence source_evidence_literature NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_provenance.
- NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_assertion SIO_000772 22802388 NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_provenance.
- NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_assertion wasDerivedFrom befree-2016 NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_provenance.
- NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_assertion wasGeneratedBy ECO_0000203 NP998056.RAyIJ0uvUcJaTjC8_SHyjXuNDNrrPE5AIq4CH9RzVyPDc130_provenance.